Peloton Therapeutics Inc. exercised an optional $22.2 million tranche of its series D round, closed in September 2016 at $52.4 million, to extend the runway for its hypoxia inducible factor-2 alpha (HIF-2 alpha) antagonists, which are targeting renal and other solid tumors.